Oral deucrictibant for preventing and treating angioedema attacks in AAE-C1INH
Treatments studied
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests two forms of an oral medication to prevent and treat sudden swelling attacks in people with a rare condition called acquired angioedema due to C1 inhibitor deficiency. It aims to see if the drug can reduce attack frequency and manage acute episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
- You have had swelling attacks in the past and are not currently using preventive treatment (or stopped it before the screening visit).
- You must be able to use an electronic device to record your symptoms daily.
- Women who can become pregnant must agree to use effective birth control; women who are pregnant, planning pregnancy, or breastfeeding cannot participate.
- You cannot have certain liver or kidney problems, uncontrolled other diseases, or a history of seizures or drug abuse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
This study tests a long-term daily pill to prevent swelling attacks in people with hereditary angioedema (HAE). The pill, called deucrictibant, is designed to block a protein involved in causing attacks. It's for adolescents and adults who want to reduce how often swelling episodes occur.
This program provides an experimental treatment called deucrictibant for people with hereditary angioedema (HAE) who have attacks that are not controlled by other approved medicines. It aims to see if this treatment can safely and effectively stop HAE attacks when other options have failed.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This trial tests a plasma-derived C1 esterase inhibitor to treat and prevent acute attacks in people with hereditary angioedema (HAE) types 1 or 2. It aims to see if the medicine can quickly relieve swelling episodes and reduce their frequency.
This trial tests if lanadelumab can prevent swelling attacks in people with acquired angioedema (AAE). Acquired angioedema is a rare condition that causes sudden swelling in the skin and other body parts. This medicine is given as a long-term shot to lower the number of attacks you have.
Hear when a new Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.